Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gabapentin versus paroxetine for functional gastrointestinal and psychological symptoms in ulcerative colitis remission
IRCT20220417054557N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in functional gastrointestinal disorder (FGID) and autoimmune colitis comparing Paroxetine with Gabapentin (2 arms). Primary endpoints: Treatment of gastrointestinal functional symptoms, Quality of life and 2 more. Started Apr 2023; status: completed.
02
Drugs
gabapentinparoxetine
03
Conditions
functional gastrointestinal disorder (FGID)autoimmune colitis
Beyond the preview
Go deeper on IRCT20220417054557N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220417054557N1.